PD184352 (CI-1040)

Name: PD184352 (CI-1040)
Brand: Selleck Chemicals
SKU: S1020
Rating: 5 (109 reviews)

For research use only.

Catalog No.S1020

109 publications

CAS No. 212631-79-3

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.

Selleck's PD184352 (CI-1040) has been cited by 109 publications

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):499-500

PubMed: 27622337 ( click the link to review the publication )

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(6):E1516

PubMed: 32531927 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 14(1)E23

PubMed: 33396632 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Food Funct, 2020, 11(3):2714-2724

PubMed: 32163057 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2358-2372

PubMed: 31461652 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

PLoS Pathog, 2019,

PubMed: 30716130 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )
Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1468

PubMed: 30728366 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

EMBO J, 2018, 37(1):19-38

PubMed: 29150432 ( click the link to review the publication )

PLoS Biol, 2018, 16(5):e2003619

PubMed: 29771909 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):320-336

PubMed: 29263201 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Gene, 2018,

PubMed: 29133145 ( click the link to review the publication )

Cell Cycle, 2018,

PubMed: 29169284 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37379-37392

PubMed: 30647839 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

FASEB J, 2017, 31(5):1903-1915

PubMed: 28174207 ( click the link to review the publication )

Antiviral Res, 2017, 142:178-184

PubMed: 28377100 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173278

PubMed: 28257460 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )
J Clin Invest, 2016, 1;126(4):1282-99

PubMed: 26974158 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Oncogene, 2016, 35(29):3854-3865

PubMed: 26657151 ( click the link to review the publication )

Cancer Discov, 2016,

PubMed: 27179038 ( click the link to review the publication )

Drug Metab Dispos, 2016, 44(5):665-71

PubMed: 26953171 ( click the link to review the publication )

Oncol Lett, 2016, 11(1):99-104

PubMed: 26870175 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48517-48532

PubMed: 27384486 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(37):E5160-8

PubMed: 26324936 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Reprod Fertil Dev, 2015, 10.1071/RD14071

PubMed: 25966803 ( click the link to review the publication )

Anim Reprod Sci, 2015, 161:47-57

PubMed: 26307658 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

eNeuro, 2015, 2(5)

PubMed: 26730399 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

EMBO Mol Med, 2014, 6(6):821-34

PubMed: 24778454 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )
Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

J Biol Chem, 2014, 289(4):2112-26

PubMed: 24311790 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

Blood, 2013, 121(19):3879-88, S1-8

PubMed: 23460614 ( click the link to review the publication )

J Clin Invest, 2013, 123(11):4786-98

PubMed: 24216509 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Allergy, 2013, 68(7):880-9

PubMed: 23742707 ( click the link to review the publication )

Dis Model Mech, 2013, 6(2):521-9

PubMed: 22996645 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )
J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

PLoS One, 2012, 7(2):e31492

PubMed: 22384029 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Neoplasia, 2011, 13(2):154-66

PubMed: 21403841 ( click the link to review the publication )

Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	NYjtWGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XaSWlEPTB;MD6wNlI4PiEQvF2=	NX3WcFRFW0GQR1XS
CHP-212	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYSzUXdPUUN3ME2wMlAzQDh3IN88US=>	NILlOIpUSU6JRWK=
EoL-1-cell	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrkfmZrUUN3ME2wMlA1OTV{IN88US=>	NF\ncZJUSU6JRWK=
DU-4475	NF7UWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnacGVKSzVyPUCuNFc2QTlizszN	MkPxV2FPT0WU
MMAC-SF	MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPEeWZKSzVyPUCuNVA6PzRizszN	M{LVXnNCVkeHUh?=
AGS	M3;WSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ezd2lEPTB;MD6xNVcyOyEQvF2=	NI\ON3ZUSU6JRWK=
M14	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMUW0Olgh\|ryP	M4HFWHNCVkeHUh?=
CP50-MEL-B	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTwN\|FKSzVyPUCuNVczPTRizszN	NXznOWJPW0GQR1XS
C32	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUmwO\|Ih\|ryP	NVvVRph{W0GQR1XS
KMOE-2	NVfNWXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLBe2pVUUN3ME2wMlE6Pzl3IN88US=>	M{PlOXNCVkeHUh?=
A101D	M330Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrvTlIxUUN3ME2wMlIyPCEQvF2=	NH7h[mpUSU6JRWK=
KM12	NFfsR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\uZmlEPTB;MD6yOFA2PyEQvF2=	Mke3V2FPT0WU
HSC-4	M{K3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMkSzPVUh\|ryP	M{fjcXNCVkeHUh?=
NOMO-1	NF:4b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXG4PHo6UUN3ME2wMlI2PzR{IN88US=>	M2m0fXNCVkeHUh?=
MZ7-mel	M{HL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMk[zOEDPxE1?	M4DXOHNCVkeHUh?=
ACN	NYPiRWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMk[3N\|ch\|ryP	NGHQfoVUSU6JRWK=
MEL-HO	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTGO2w2UUN3ME2wMlI4PjV{IN88US=>	NIXPWWpUSU6JRWK=
BHT-101	M1;0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMki2NFYh\|ryP	M2qwTXNCVkeHUh?=
SK-MEL-28	NH\qS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\F[lhKSzVyPUCuN\|A1ODlizszN	MnmzV2FPT0WU
KG-1	NWHVWIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TlOmlEPTB;MD6zNFY3QCEQvF2=	NGDn[XFUSU6JRWK=
COLO-679	NIPHTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUW3TlZZUUN3ME2wMlMzPzJizszN	MXrTRW5ITVJ?
SK-MEL-24	NFzWZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\IOZJMUUN3ME2wMlMzQDF\|IN88US=>	MWXTRW5ITVJ?
G-361	M1jh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwM{[3PVUh\|ryP	M1PUc3NCVkeHUh?=
KY821	NWLyNnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;UemFKSzVyPUCuN\|c6OSEQvF2=	NHnMcIxUSU6JRWK=
KASUMI-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTvUlZKSzVyPUCuN\|k6KM7:TR?=	MWjTRW5ITVJ?
HL-60	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDae41tUUN3ME2wMlQyOTB5IN88US=>	NUP2[mw2W0GQR1XS
K5	M1W0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Ttc2lEPTB;MD60N\|EyPyEQvF2=	NUjOfHdRW0GQR1XS
KU812	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNEWyPVkh\|ryP	NV;xSmZtW0GQR1XS
SH-4	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rGZmlEPTB;MD60OlI2PiEQvF2=	NH;X[Y5USU6JRWK=
HTC-C3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoL0TWM2OD1yLkS2OVMyKM7:TR?=	MYfTRW5ITVJ?
CP66-MEL	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwNEi4NFkh\|ryP	MUnTRW5ITVJ?
WM-115	M1Prb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjNNXJSUUN3ME2wMlQ6OjV5IN88US=>	M3Ox[XNCVkeHUh?=
A2780	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwNEm4NlMh\|ryP	MmqwV2FPT0WU
P12-ICHIKAWA	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\XTWM2OD1yLk[xNlIyKM7:TR?=	MXjTRW5ITVJ?
HMV-II	NUHaN3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3pTWM2OD1yLk[0OFY2KM7:TR?=	M{j1dHNCVkeHUh?=
HT-144	MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvNc\|lKSzVyPUCuOlQ3PTdizszN	NYXJbFlxW0GQR1XS
LB2518-MEL	NWjF[GxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIThU3hKSzVyPUCuO\|E3OzJizszN	M2HZdXNCVkeHUh?=
NCI-SNU-1	M2j4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LrVWlEPTB;MD63OVQ{OyEQvF2=	MXXTRW5ITVJ?
C2BBe1	M4TVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwOEGwNlMh\|ryP	Ml;IV2FPT0WU
PSN1	NUTndJg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHD[mRKSzVyPUCuPVYyQTZizszN	MmDNV2FPT0WU
UACC-257	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwOU[0O\|Mh\|ryP	NWf2dHBIW0GQR1XS
RVH-421	NH\Hb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[wdoJKSzVyPUCuPVcyQCEQvF2=	M4HtTnNCVkeHUh?=
GP5d	MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwOUizNFgh\|ryP	M4XDb3NCVkeHUh?=
TYK-nu	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwMEOxO\|Ih\|ryP	NU\xOmpUW0GQR1XS
SK-N-AS	M2nJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2q3RWlEPTB;MT6wO\|k1PyEQvF2=	MoHNV2FPT0WU
SW620	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILWVY5KSzVyPUGuNVM2OzRizszN	MlnDV2FPT0WU
HuP-T4	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr4TWM2OD1zLkG4N\|U6KM7:TR?=	MlfQV2FPT0WU
A549	NYnsPW85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PhXmlEPTB;MT6xPVU4PiEQvF2=	NF;PdZRUSU6JRWK=
Mewo	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLZTWM2OD1zLkKwNlc3KM7:TR?=	NEf6dmJUSU6JRWK=
ONS-76	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTFwMkKwOFkh\|ryP	MmDEV2FPT0WU
SK-MEL-1	M4PEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTFwMkO0NVkh\|ryP	MUfTRW5ITVJ?
RCM-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ftdGlEPTB;MT6yOFA1PyEQvF2=	MXfTRW5ITVJ?
H-EMC-SS	M{nneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjRZpNPUUN3ME2xMlI6PjB6IN88US=>	MVnTRW5ITVJ?
NCI-H2291	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XYe2lEPTB;MT6zNlU{PiEQvF2=	M2jpWnNCVkeHUh?=
SW1463	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDvOGk3UUN3ME2xMlM{PzJzIN88US=>	NF;2SXlUSU6JRWK=
LS-411N	NX7RTHhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3nd2pmUUN3ME2xMlQxPTF5IN88US=>	M{XKSXNCVkeHUh?=
BV-173	NGroNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL1XVljUUN3ME2xMlQ1ODF3IN88US=>	MVHTRW5ITVJ?
LS-513	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTFwNEWxPVIh\|ryP	NEjWTIxUSU6JRWK=
LoVo	NIK5dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFwNE[zPVkh\|ryP	NF7OV4xUSU6JRWK=
HO-1-N-1	M1XDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:0[45KSzVyPUGuOVE3OzRizszN	MnHuV2FPT0WU
ML-2	M{nTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTFwNUK4Olgh\|ryP	M4W2WXNCVkeHUh?=
NCI-H1437	NGf6[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTFwNUWyO\|Uh\|ryP	MnzkV2FPT0WU
SW1116	NIjmR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHn[ml{UUN3ME2xMlU3Ozl6IN88US=>	NWDUXGxIW0GQR1XS
A4-Fuk	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;EUXRKSzVyPUGuOVcxPDVizszN	M{\MOXNCVkeHUh?=
HD-MY-Z	NX3JdJcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfUbmQ2UUN3ME2xMlU4Ozd4IN88US=>	M{SwUnNCVkeHUh?=
SK-MEL-2	M4D6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\jdY5kUUN3ME2xMlU4PDV7IN88US=>	M1\1WnNCVkeHUh?=
RT-112	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTFwNUi5OVIh\|ryP	NUOxRnV5W0GQR1XS
COLO-829	M4LJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7STWM2OD1zLk[yNlMzKM7:TR?=	NXfBTXhsW0GQR1XS
OVCAR-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1u5R2lEPTB;MT63O\|Y5PyEQvF2=	MnHZV2FPT0WU
NB69	NHfXVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTzTWM2OD1zLke4OFY6KM7:TR?=	M2DQVXNCVkeHUh?=
NCI-H292	M4iwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYKwS3FnUUN3ME2xMlg3Pjl7IN88US=>	NELoUG1USU6JRWK=
LOXIMVI	NWT2U4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj3bGpSUUN3ME2xMlg6PDJ5IN88US=>	NWG4OGc4W0GQR1XS
BPH-1	M3nhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHmTWM2OD1zLki5OVkyKM7:TR?=	M2ryR3NCVkeHUh?=
A375	M{nINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDmNGtKSzVyPUGuPFk4OTRizszN	NHnDZmpUSU6JRWK=
LCLC-97TM1	Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK1XY1zUUN3ME2xMlkzOjV4IN88US=>	Mom2V2FPT0WU
RXF393	NG\GV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HQbGlEPTB;MT65O\|g5PyEQvF2=	MVLTRW5ITVJ?
HCC70	M3XpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTJwMEK0NlYh\|ryP	Mn\zV2FPT0WU
EM-2	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36wfWlEPTB;Mj6wO\|E6QCEQvF2=	MX7TRW5ITVJ?
MZ2-MEL	M4jxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fvfGlEPTB;Mj6xNVEzPyEQvF2=	MoPRV2FPT0WU
HN	NIH2SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HyUWlEPTB;Mj6xOlI4QCEQvF2=	MnvmV2FPT0WU
A2058	NInwZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTqfJFKSzVyPUKuNVkzPzlizszN	NUDBUZpUW0GQR1XS
NB7	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnCS4hKSzVyPUKuN\|QxQDZizszN	MnvIV2FPT0WU
DOK	NXvoRpQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HmW2lEPTB;Mj6zOVc4OyEQvF2=	NFS5UFJUSU6JRWK=
CAL-27	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoSxTWM2OD1{LkO5NlM3KM7:TR?=	NYHSOXVMW0GQR1XS
BB65-RCC	NXnjUZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnkXHZKSzVyPUKuOFA3PzRizszN	M3fadHNCVkeHUh?=
RD	NF3KWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7UTWM2OD1{LkS0O\|I{KM7:TR?=	MlXTV2FPT0WU
KNS-62	NXvibpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTJwNUGxOlQh\|ryP	M4qxdnNCVkeHUh?=
EW-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LPdWlEPTB;Mj61OlM{QSEQvF2=	M4H1VHNCVkeHUh?=
DB	NV3BfIwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTJwNUi3PFgh\|ryP	MkS3V2FPT0WU
HCC2218	NXrzRVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD6WXlCUUN3ME2yMlY1Pzd6IN88US=>	MV;TRW5ITVJ?
L-363	NGG2SWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTYTo1SUUN3ME2yMlc1OzdizszN	M4L5NXNCVkeHUh?=
CHL-1	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYntN\|dCUUN3ME2yMlgxPzh3IN88US=>	MoHhV2FPT0WU
BFTC-905	M1rSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFO1bIdKSzVyPUKuPFI2OyEQvF2=	NI\SbIRUSU6JRWK=
HCE-T	NUfnfGhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkX3TWM2OD1{LkizNlY1KM7:TR?=	NXztXYZGW0GQR1XS
COLO-792	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLXTWM2OD1{Lki0NFI4KM7:TR?=	NFHld\|NUSU6JRWK=
LB2241-RCC	M4e5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX22PGhtUUN3ME2yMlg2QDl\|IN88US=>	NXToWm9OW0GQR1XS
CAL-39	M4P6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTJwOEm5PVkh\|ryP	NXTJRXk4W0GQR1XS
T-24	MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTJwOUGxNVIh\|ryP	M2XDWHNCVkeHUh?=
NCI-H727	M1jkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTJTWM2OD1{LkmxO\|k3KM7:TR?=	MnLmV2FPT0WU
Ca9-22	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPaTWM2OD1{Lkm3NlU2KM7:TR?=	MV\TRW5ITVJ?
MIA-PaCa-2	MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3y1fGlEPTB;Mz6wNFc5OSEQvF2=	NFT4dFZUSU6JRWK=
HT-1080	NH23dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX6TWM2OD1\|LkCxPVk4KM7:TR?=	NW\uNHdiW0GQR1XS
D-423MG	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTNwMEe3OVMh\|ryP	MmLOV2FPT0WU
LAMA-84	NGXHeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHGbFhKSzVyPUOuNVM2QCEQvF2=	NGfSbIVUSU6JRWK=
SW780	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\0TWM2OD1\|LkG0NlI6KM7:TR?=	M37aN3NCVkeHUh?=
KU-19-19	NEm5fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHhd2RjUUN3ME2zMlE4ODN2IN88US=>	NVrnelVUW0GQR1XS
COLO-741	MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELUenpKSzVyPUOuNVg3PzNizszN	NIe2[5hUSU6JRWK=
HSC-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHTTWM2OD1\|LkKzNVUyKM7:TR?=	M4H5SHNCVkeHUh?=
SN12C	NV3ROIl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrjbIJpUUN3ME2zMlI1PzBzIN88US=>	MYDTRW5ITVJ?
786-0	NEXkWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoraTWM2OD1\|LkK3NlQ{KM7:TR?=	MnvZV2FPT0WU
GAK	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPQXm5KSzVyPUOuN\|I2PjFizszN	Mlu5V2FPT0WU
PANC-03-27	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3uzPWlEPTB;Mz6zOVA1PSEQvF2=	MUjTRW5ITVJ?
CTB-1	NFXifWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrXd3E2UUN3ME2zMlQ4ODR5IN88US=>	MnzzV2FPT0WU
A427	M4Hqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLtbFRZUUN3ME2zMlU6PTV4IN88US=>	M4X2d3NCVkeHUh?=
EGI-1	M4Xqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2e3U2lEPTB;Mz62NFU5OyEQvF2=	NVnW[HJ2W0GQR1XS
U-2-OS	NYPEPHZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\tPXpKSzVyPUOuOlczPTZizszN	NH7Pc49USU6JRWK=
NCI-SNU-5	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNwNke3N{DPxE1?	MVrTRW5ITVJ?
SK-LU-1	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTNwNki3PVgh\|ryP	MWHTRW5ITVJ?
697	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjPZWlKSzVyPUOuOlk3ODNizszN	M3ewS3NCVkeHUh?=
HPAF-II	NILsdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTNwN{W0PUDPxE1?	NY\Mdo1bW0GQR1XS
NCI-H2087	NWDGNoJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDxTWM2OD1\|Lki0OlczKM7:TR?=	NF3Hfo9USU6JRWK=
SK-MEL-3	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTNwOEWxOVQh\|ryP	MX;TRW5ITVJ?
CGTH-W-1	NVnlPY82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTrTWM2OD1\|Lki1O\|I2KM7:TR?=	M{[wUXNCVkeHUh?=
8505C	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D1TWlEPTB;Mz65NFA4QCEQvF2=	MmjYV2FPT0WU
GAMG	NFfEOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTRwMEKzO\|ch\|ryP	NIXoVI1USU6JRWK=
SW626	NUHlTmxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTiTGVUUUN3ME20MlA1PDhizszN	MX3TRW5ITVJ?
CAL-62	NFvj[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DabmlEPTB;ND6wO\|Q{KM7:TR?=	MlG0V2FPT0WU
MHH-PREB-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4frRWlEPTB;ND6xNlEyOSEQvF2=	NYrSXIgxW0GQR1XS
RPMI-7951	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7icYJ1UUN3ME20MlI2PTh7IN88US=>	M4X1bnNCVkeHUh?=
HOP-92	NFLWNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTRwMkW2O{DPxE1?	MkLMV2FPT0WU
MDA-MB-231	NHTUTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTRwMkmyNlMh\|ryP	MlH3V2FPT0WU
LAN-6	MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTRwM{G2N\|ch\|ryP	MlPlV2FPT0WU
ALL-PO	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vlOGlEPTB;ND6zOlE2PiEQvF2=	MXzTRW5ITVJ?
HH	NV;HfIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIX4R5lKSzVyPUSuOFE2QTdizszN	MmnsV2FPT0WU
IGROV-1	MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoftTWM2OD12LkS1NVcyKM7:TR?=	NHTBcJNUSU6JRWK=
NCI-H358	MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIS3Z4tKSzVyPUSuOFU{QDVizszN	NXTHUYpkW0GQR1XS
NB5	NUnSXJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\uTHFKSzVyPUSuOlA{PjlizszN	NXjuboROW0GQR1XS
NCI-H747	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjGd41QUUN3ME20MlY5QDB5IN88US=>	NHvjWIhUSU6JRWK=
NH-12	M{jsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PvfmlEPTB;ND63NVYzPSEQvF2=	MYrTRW5ITVJ?
LB1047-RCC	NXfzSo82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDtU2pKSzVyPUSuO\|M5OTVizszN	MlT5V2FPT0WU
EFO-27	NV\jOo1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[xbnRKSzVyPUSuO\|g3PjdizszN	MVPTRW5ITVJ?
EPLC-272H	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrlUVVrUUN3ME20Mlk6PjZ7IN88US=>	M2TaTnNCVkeHUh?=
CAL-54	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXzWI9KSzVyPUWuNFI3QTVizszN	NFqyeodUSU6JRWK=
H4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojOTWM2OD13LkC0NlU2KM7:TR?=	MXrTRW5ITVJ?
MOLT-13	M2Czd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTVwME[3O\|Yh\|ryP	NU\neoN7W0GQR1XS
CAL-33	NGPYNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17aWWlEPTB;NT6xNlMyPyEQvF2=	M4m1O3NCVkeHUh?=
23132-87	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\sUlNKSzVyPUWuNVY5PzJizszN	MlnMV2FPT0WU
UM-UC-3	NX;aS5U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnlTWM2OD13LkG4NFQ4KM7:TR?=	NWe5fJRxW0GQR1XS
HuH-7	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PMWmlEPTB;NT6yO\|E1PyEQvF2=	NWnOS4t7W0GQR1XS
BCPAP	M3y3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr2eZlKSzVyPUWuN\|I6PjlizszN	NILHOW1USU6JRWK=
AsPC-1	M{L4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[ySlA4UUN3ME21MlM3PzZ\|IN88US=>	NWrJW2pnW0GQR1XS
NCI-H1155	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;6TWM2OD13LkSwNFUyKM7:TR?=	NHj3bmJUSU6JRWK=
GT3TKB	M{TDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\TTWM2OD13LkS2OVk5KM7:TR?=	NWLtOlBWW0GQR1XS
HCC2998	NIjWRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXRclJsUUN3ME21MlQ6OTB7IN88US=>	NYrHWIpTW0GQR1XS
NUGC-3	M4\NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELOSnBKSzVyPUWuOFk{ODJizszN	MWHTRW5ITVJ?
Hs-578-T	NIPHemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTVwNUO3PVQh\|ryP	NXS3W45YW0GQR1XS
FADU	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrWOodNUUN3ME21MlU2PzJ4IN88US=>	NGfGbFNUSU6JRWK=
NBsusSR	NHvaWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjn[ms4UUN3ME21MlU4OTV3IN88US=>	M{GyS3NCVkeHUh?=
ME-180	M1rCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrtNXdKSzVyPUWuOVgxQTJizszN	NFvzTHJUSU6JRWK=
SW1710	M3Tobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X3VGlEPTB;NT62NVY2PCEQvF2=	MkLUV2FPT0WU
HuP-T3	M4Lrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfjTWM2OD13Lk[yNFI6KM7:TR?=	NWTsfIlvW0GQR1XS
HOS	M4ryOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTVwNkK5NlMh\|ryP	M2PkZXNCVkeHUh?=
PA-1	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\iU5lQUUN3ME21MlY1OjZ3IN88US=>	M4X0[3NCVkeHUh?=
LU-99A	NGf5e41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTVwNk[0OVEh\|ryP	NUfLZmtPW0GQR1XS
RS4-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTVwNk[3O\|Uh\|ryP	MlLOV2FPT0WU
TE-8	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLHTWM2OD13Lk[4OVM4KM7:TR?=	NGKwb2FUSU6JRWK=
RERF-LC-MS	M1TIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LnS2lEPTB;NT62PFgxOyEQvF2=	NVHObWhwW0GQR1XS
MEL-JUSO	NWexVIh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrufIRKSzVyPUWuO\|M4QCEQvF2=	M1PwZ3NCVkeHUh?=
SK-MES-1	NFuwVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHteZZ3UUN3ME21Mlg{PTJ6IN88US=>	MXHTRW5ITVJ?
D-263MG	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTVwOEizOVEh\|ryP	MWXTRW5ITVJ?
NB10	NY\3cYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nLc2lEPTB;NT64PVQ3KM7:TR?=	M{XrPHNCVkeHUh?=
SK-HEP-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTVwOUO0O\|Eh\|ryP	MWLTRW5ITVJ?
HT-29	NVrGdGs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTVwOUixNVgh\|ryP	M3;0fnNCVkeHUh?=
KYSE-140	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\ITWM2OD14LkCyNVgzKM7:TR?=	MX7TRW5ITVJ?
NCI-H1666	NYrtPFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHUXIhKSzVyPU[uNFg1PjFizszN	NEnNRlZUSU6JRWK=
NCI-H1304	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUi5[nlFUUN3ME22MlE6QTRizszN	MkTxV2FPT0WU
RPMI-8866	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LERWlEPTB;Nj6yNVMyOyEQvF2=	M{jXTXNCVkeHUh?=
MV-4-11	NXLoZ5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13rVmlEPTB;Nj6yN\|E6QSEQvF2=	Mk[2V2FPT0WU
A431	NG\yWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjiPIdEUUN3ME22MlI1Ojl4IN88US=>	NWLGZmhqW0GQR1XS
PANC-10-05	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfa[lhCUUN3ME22MlI5OzZ\|IN88US=>	NYPQNVRCW0GQR1XS
TK10	NWO1eFZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLYTWM2OD14LkOyOlA1KM7:TR?=	NGDBfGVUSU6JRWK=
NCI-H1975	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3OwO2lEPTB;Nj60O\|IyPSEQvF2=	MW\TRW5ITVJ?
A172	NIrB[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPjTWM2OD14LkS5NVc3KM7:TR?=	MXTTRW5ITVJ?
D-566MG	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\oeGw6UUN3ME22MlU1OzB\|IN88US=>	NWLIOZF4W0GQR1XS
NCI-H2122	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\CNoJzUUN3ME22MlYyPTJ6IN88US=>	M1r1T3NCVkeHUh?=
COR-L105	NHu4c25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWq3SmxoUUN3ME22MlY2Ojd3IN88US=>	Ml;KV2FPT0WU
AN3-CA	NFvlVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7Y[\|AxUUN3ME22MlY5PjRzIN88US=>	NYLFU2lQW0GQR1XS
Calu-6	NUS1U5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\EXW9yUUN3ME22Mlc6Pjl6IN88US=>	NVT5WlgxW0GQR1XS
HCT-116	NEnLZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTxR2hRUUN3ME22MlgyOjZ2IN88US=>	NGfyXlRUSU6JRWK=
MHH-NB-11	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jTd2lEPTB;Nj64OVAxOiEQvF2=	Mmn5V2FPT0WU
MFE-280	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7WTWM2OD14Lki1PVg{KM7:TR?=	Mn7ZV2FPT0WU
SW1088	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlS1TWM2OD14LkmxPVE{KM7:TR?=	M3\acnNCVkeHUh?=
SW48	M1rGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWK3fHVyUUN3ME22Mlk1PTFizszN	NHe3fWRUSU6JRWK=
HuCCT1	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTdwMEGwN\|ch\|ryP	M1rDeHNCVkeHUh?=
ACHN	NEm1TVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTITWM2OD15LkCyPVQ{KM7:TR?=	M{fScHNCVkeHUh?=
8305C	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TpU2lEPTB;Nz6wPVk6PSEQvF2=	M1n3T3NCVkeHUh?=
DoTc2-4510	NXnCVGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVG1XI9EUUN3ME23MlEzOTVizszN	Mn3pV2FPT0WU
COR-L23	NVLsPYtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrwTWM2OD15LkK0OFIh\|ryP	MmjjV2FPT0WU
SK-MEL-30	NGj2eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf3TWM2OD15LkK1NFg{KM7:TR?=	NILMc\|lUSU6JRWK=
BE-13	MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfXXWxKSzVyPUeuN\|M5OzRizszN	NGfO[pNUSU6JRWK=
GR-ST	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTdwNECxO\|Qh\|ryP	M1v4e3NCVkeHUh?=
LU-135	NGfjSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\jXGlEPTB;Nz61OVk{QSEQvF2=	M4\WXXNCVkeHUh?=
U-266	NIrvNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\ufJNRUUN3ME23MlU3Ojh4IN88US=>	MoHWV2FPT0WU
NCI-H1355	M4PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfVem9KSzVyPUeuOVg3OzVizszN	NXL4XYJMW0GQR1XS
NB14	NHT5dVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;LTWM2OD15Lk[2OlQzKM7:TR?=	NY\yVnIxW0GQR1XS
SCC-25	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTdwN{C5JO69VQ>?	NW\hVHFrW0GQR1XS
COLO-678	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVX1ToI3UUN3ME23MlcyODd4IN88US=>	NWC2T\|RLW0GQR1XS
TGBC1TKB	M1\pNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkf4TWM2OD15Lki5N\|k5KM7:TR?=	NH;p[mxUSU6JRWK=
IST-MEL1	NWi2NZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\ZTWM2OD16LkCwOFA3KM7:TR?=	MX7TRW5ITVJ?
ECC10	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvYPWhKSzVyPUiuNFM{QTVizszN	NVnZTYhvW0GQR1XS
EW-16	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MomwTWM2OD16LkC4OFQ2KM7:TR?=	MnvoV2FPT0WU
DOHH-2	M2O0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfmTWM2OD16LkKwNFk2KM7:TR?=	NIC1[3ZUSU6JRWK=
NCI-H1581	NGLadGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrzZmluUUN3ME24MlI3OzJ\|IN88US=>	NFnKdZJUSU6JRWK=
TE-5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fvS2lEPTB;OD60NlQzQSEQvF2=	MlTDV2FPT0WU
CAKI-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRThwNUeyNlIh\|ryP	M1i3cnNCVkeHUh?=
A673	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnUZWFwUUN3ME24MlY{OjB{IN88US=>	NInMUW1USU6JRWK=
CAL-12T	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LPeWlEPTB;OD62OVc2OyEQvF2=	MmTSV2FPT0WU
DBTRG-05MG	NUP6RoV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHuepNKSzVyPUiuO\|Q5PTlizszN	NUix[2d3W0GQR1XS
SK-N-FI	M3\k[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLCNYJKSzVyPUiuPFE{PzlizszN	MlruV2FPT0WU
K-562	NUnEWHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPzUIVKSzVyPUiuPFM6PTdizszN	NULhRW9ZW0GQR1XS
SBC-1	NIj1eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3jPFJKSzVyPUiuPFY3PDVizszN	NHfabY5USU6JRWK=
ES4	NEjjToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXGTXVKSzVyPUiuPFY5QDRizszN	MX7TRW5ITVJ?
MS-1	NU\sWHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRThwOEe1NVch\|ryP	MYfTRW5ITVJ?
RKO	MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULvS5lSUUN3ME24Mlg6ODV5IN88US=>	NGHXe5NUSU6JRWK=
NCI-H1693	NFL4[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrVTYt1UUN3ME24MlkzOTdizszN	M4\5[HNCVkeHUh?=
SW954	MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrLUVVKSzVyPUiuPVY6PzhizszN	NWSweWxsW0GQR1XS
SK-UT-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDYcIpKSzVyPUiuPVc3QDNizszN	M4\S[3NCVkeHUh?=
T98G	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjpXXhKSzVyPUiuPVk5PDZizszN	MUPTRW5ITVJ?
NCI-H2126	NUHqUXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTlwMEC4NlYh\|ryP	MoHvV2FPT0WU
TE-12	NWXXNmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz1ZWRKSzVyPUmuNFM{PjdizszN	MmXWV2FPT0WU
DK-MG	NGDFZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTlwMkGxPVEh\|ryP	NUW2[Zc5W0GQR1XS
MEG-01	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPoVWZKSzVyPUmuNlQ6OzFizszN	NETEe4lUSU6JRWK=
HCC1937	M2nOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTlwMkmwPVEh\|ryP	M2OxZXNCVkeHUh?=
MKN45	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjrWWxuUUN3ME25MlQ2ODZ3IN88US=>	MW\TRW5ITVJ?
NCI-H1792	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1n4V2lEPTB;OT60OVIyQSEQvF2=	Mn7FV2FPT0WU
SW1417	NWnmXlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTpfGRtUUN3ME25MlU3QDN5IN88US=>	M3XKeHNCVkeHUh?=
639-V	NEDw[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTlwNkSzPFgh\|ryP	M{D5W3NCVkeHUh?=
P30-OHK	NX3RNXI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv4TWM2OD17Lk[1N\|E3KM7:TR?=	M2PYNHNCVkeHUh?=
YKG-1	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jQRWlEPTB;OT63OVA{OyEQvF2=	MlG2V2FPT0WU
KGN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrZNFNKSzVyPUmuPFM4QTVizszN	M1\EVHNCVkeHUh?=
MSTO-211H	NVLYWmU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITMXmpKSzVyPUmuPVU2OjlizszN	NVPIZnFMW0GQR1XS
NCI-H1573	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml25TWM2OD1zMD6xOVc1KM7:TR?=	MVXTRW5ITVJ?
NCI-H720	NIPMfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV21WphCUUN3ME2xNE4yQTh7IN88US=>	M3HOPXNCVkeHUh?=
KARPAS-45	NWjsWYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PZOmlEPTB;MUCuNlc6PSEQvF2=	NGDtToZUSU6JRWK=
MDA-MB-175-VII	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\HN\|d6UUN3ME2xNE41QCEQvF2=	NVHXeZk6W0GQR1XS
SK-NEP-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLRTWM2OD1zMD60PVgyKM7:TR?=	NGCxS\|NUSU6JRWK=
MKN28	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\WTWM2OD1zMD61NVgh\|ryP	MnnPV2FPT0WU
KYSE-520	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTFyLkWyJO69VQ>?	Mn7zV2FPT0WU
KE-37	M4f4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvrTWM2OD1zMD61NlczKM7:TR?=	MnvoV2FPT0WU
VA-ES-BJ	NYLxW4JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfxTWM2OD1zMD61Olch\|ryP	NIfldGxUSU6JRWK=
CCRF-CEM	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK0RnZtUUN3ME2xNE42Pjh2IN88US=>	MkHaV2FPT0WU
GMS-10	MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX6NHVKSzVyPUGwMlYxQTRizszN	NHvJR5hUSU6JRWK=
NCI-H1623	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XLcWlEPTB;MUCuOlM4QSEQvF2=	NIe4OmpUSU6JRWK=
NEC8	NIPD[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHqTWM2OD1zMD63O\|c{KM7:TR?=	MoLDV2FPT0WU
MOLT-16	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj6TWM2OD1zMD64NVE{KM7:TR?=	MVrTRW5ITVJ?
DJM-1	M1:0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPJN2RKSzVyPUGxMlA{PzlizszN	NFLJTVhUSU6JRWK=
U251	NWDLd4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPNcnROUUN3ME2xNU4xPDJizszN	Mnu3V2FPT0WU
SBC-5	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTFzLkG0Olch\|ryP	M3PMOHNCVkeHUh?=
SW756	NInYVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXaTWM2OD1zMT6yNVU1KM7:TR?=	NF3OfWdUSU6JRWK=
KS-1	NXn5RXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPSU2JqUUN3ME2xNU4zPjF7IN88US=>	NWHRbZZpW0GQR1XS
SF295	NVnTWYFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHL1[ZNKSzVyPUGxMlMyODRizszN	Mny2V2FPT0WU
YH-13	NIPTb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCzeIhJUUN3ME2xNU4{OjZ5IN88US=>	MkjyV2FPT0WU
SW837	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XIcmlEPTB;MUGuN\|UxPiEQvF2=	NHzONGdUSU6JRWK=
KYSE-450	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXs[mZKSzVyPUGxMlQxPTdizszN	MXHTRW5ITVJ?
KYSE-180	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITtTFZKSzVyPUGxMlQ5OiEQvF2=	MmTmV2FPT0WU
S-117	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTFzLkS4PVYh\|ryP	M33IO3NCVkeHUh?=
KOSC-2	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrjNZJxUUN3ME2xNU43OjJ{IN88US=>	MX\TRW5ITVJ?
KYSE-270	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7qSVFKSzVyPUGxMlg4PDVizszN	NFK2d2RUSU6JRWK=
D-336MG	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\hXlVIUUN3ME2xNU46ODd3IN88US=>	NIjOSWdUSU6JRWK=
KALS-1	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTF{LkCwNVYh\|ryP	M2nFfnNCVkeHUh?=
LB373-MEL-D	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTF{LkC1N\|Mh\|ryP	NHrZbGdUSU6JRWK=
HLE	M3qzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDoc2ZQUUN3ME2xNk4xPTh3IN88US=>	MWnTRW5ITVJ?
SJSA-1	M1nLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrxZlVKSzVyPUGyMlA4OzVizszN	M4XLXnNCVkeHUh?=
SW1990	NV72SpJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[4TWM2OD1zMj6wPVEyKM7:TR?=	M3XPPHNCVkeHUh?=
NOS-1	M{XLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTF{LkGzOVIh\|ryP	MmHoV2FPT0WU
GI-ME-N	M2roWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF{LkKxOlMh\|ryP	NU\aVXhOW0GQR1XS
NCI-H1703	NX;TN5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX3VpZ5UUN3ME2xNk4zPjF4IN88US=>	M3T4WHNCVkeHUh?=
ES7	NVT6[XM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHzemlbUUN3ME2xNk4zPzJ2IN88US=>	NI\RNVZUSU6JRWK=
KYSE-510	MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvCTWM2OD1zMj61NFc6KM7:TR?=	NXvSbnloW0GQR1XS
BHY	NVjyVWc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTF{LkWzNFch\|ryP	Ml6wV2FPT0WU
TCCSUP	M2jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTF{LkW3OVch\|ryP	MluwV2FPT0WU
HSC-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3pNo5nUUN3ME2xNk42QTl4IN88US=>	NET0WGtUSU6JRWK=
BEN	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2WySGlEPTB;MUKuOlE1OyEQvF2=	MmTSV2FPT0WU
769-P	NYnsV2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF{Lke5NlQh\|ryP	NFXiU4ZUSU6JRWK=
HT	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm1Vo5wUUN3ME2xNk45OzR4IN88US=>	NHfxcZNUSU6JRWK=
LXF-289	NXf4WowyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nnc2lEPTB;MUKuPVU{OSEQvF2=	NEPuSIlUSU6JRWK=
OVCAR-3	NIPPS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTF{Lkm1Olch\|ryP	M{LUbHNCVkeHUh?=
ATN-1	M1zEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\nXpFKSzVyPUGzMlAyQDRizszN	M3vqb3NCVkeHUh?=
8-MG-BA	NXXGfVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\TcolKSzVyPUGzMlA1PTVizszN	MlXNV2FPT0WU
SW13	M1SxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHrT4ZKSzVyPUGzMlEyPjVizszN	NHvMc4VUSU6JRWK=
NCI-H1092	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXUTWM2OD1zMz6xOlIh\|ryP	NH:0bYFUSU6JRWK=
OAW-42	M3vnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTF\|LkG5N\|ch\|ryP	NHLMN\|BUSU6JRWK=
NCI-H2452	NUPCVpVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX61N25DUUN3ME2xN{4zOTd3IN88US=>	NY\0TXZXW0GQR1XS
CAPAN-1	NXm3OoZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DLOmlEPTB;MUOuOVUyPCEQvF2=	NHjt[VFUSU6JRWK=
NCI-H2009	NGfuUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX72SG9mUUN3ME2xN{42QTF7IN88US=>	M1K4OHNCVkeHUh?=
SF268	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLsTWM2OD1zMz62N\|I3KM7:TR?=	Mk\DV2FPT0WU
GCIY	MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fQT2lEPTB;MUOuOlkzPyEQvF2=	NXzzW\|lRW0GQR1XS
OS-RC-2	M4HJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTF\|Lkm1NFEh\|ryP	NUPYNGNxW0GQR1XS
GCT	NWX6bGU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHxTphNUUN3ME2xN{46Pjl5IN88US=>	M2ixdnNCVkeHUh?=
NB17	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rGO2lEPTB;MUSuNFg2KM7:TR?=	M3PHfXNCVkeHUh?=
NCI-H2030	M3KxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DmbGlEPTB;MUSuNVQ3PSEQvF2=	NVzvfmhuW0GQR1XS
HC-1	M3vjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3H0S2lEPTB;MUSuNlA5PyEQvF2=	MV\TRW5ITVJ?
QIMR-WIL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW0TWM2OD1zND6zOFEzKM7:TR?=	MUnTRW5ITVJ?
Capan-2	Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfROHl4UUN3ME2xOE4{PzF2IN88US=>	M{j1PHNCVkeHUh?=
BALL-1	NIXOUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;zTWM2OD1zND60OlY2KM7:TR?=	NFrmdpVUSU6JRWK=
LS-1034	NUfDdnhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LNTmlEPTB;MUSuOlE2OiEQvF2=	NHvCW49USU6JRWK=
U-118-MG	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTF2Lk[zNUDPxE1?	NVnnSZZYW0GQR1XS
NCI-H630	M{[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHSPWY5UUN3ME2xOE43PTZ6IN88US=>	NWTGcW1nW0GQR1XS
OVCAR-8	NITUPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXH2To5OUUN3ME2xOE44OjBzIN88US=>	MV7TRW5ITVJ?
NCI-H2347	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTF2LkiyN{DPxE1?	M1zNdHNCVkeHUh?=
BT-549	NYLpUYpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTF2LkiyPFQh\|ryP	NYe0VHIyW0GQR1XS
LB831-BLC	M{TyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H0N2lEPTB;MUSuPFk{PCEQvF2=	NGrHemVUSU6JRWK=
NCI-H661	NVT1ZnZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L0NWlEPTB;MUSuPVU6KM7:TR?=	NEC1SZVUSU6JRWK=
MKN7	M2LFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnnNVVKSzVyPUG1MlAxQTNizszN	NVvpTZVYW0GQR1XS
U-87-MG	NGXKfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PJVmlEPTB;MUWuNFg6PyEQvF2=	NYHSVpNIW0GQR1XS
OVCAR-4	NYjBfnJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPZTWM2OD1zNT6xOFI1KM7:TR?=	NVPzVlByW0GQR1XS
OE33	M3PVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfZTWM2OD1zNT6xO\|EyKM7:TR?=	NEnBO4VUSU6JRWK=
EC-GI-10	M4e5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTyWJFsUUN3ME2xOU4zOzV5IN88US=>	NV7pe5RQW0GQR1XS
AM-38	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDQWYFuUUN3ME2xOU4zPzF5IN88US=>	NV[0d45iW0GQR1XS
NCI-H1563	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X3NWlEPTB;MUWuN\|Q6KM7:TR?=	NEfCPGdUSU6JRWK=
SCC-4	MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTFU5dSUUN3ME2xOU41OTB\|IN88US=>	MoPzV2FPT0WU
Detroit562	NGCySldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfyTWM2OD1zNT60OVQ4KM7:TR?=	NYLkOllxW0GQR1XS
PC-14	NHPxTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHez[3JKSzVyPUG1MlQ5PjZizszN	M4PVT3NCVkeHUh?=
ES3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4j6ZWlEPTB;MUWuOVM3KM7:TR?=	NIr0eJZUSU6JRWK=
OCI-AML2	NXP3NWFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;wTWM2OD1zNT63OlE1KM7:TR?=	NVjnc251W0GQR1XS
LU-134-A	NWjyT2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL1c\|hKSzVyPUG1MlkxOThizszN	MlvWV2FPT0WU
SAS	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTF3LkmzO\|Mh\|ryP	MYPTRW5ITVJ?
TGBC11TKB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITlXGhKSzVyPUG1Mlk1OTRizszN	Ml3PV2FPT0WU
HOP-62	M3iw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHxTWM2OD1zNT65OVk4KM7:TR?=	MoO0V2FPT0WU
G-401	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT0PZMzUUN3ME2xOU46PjR7IN88US=>	MYDTRW5ITVJ?
NCI-H28	M3HpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTF4LkC4OVYh\|ryP	NULrWnRZW0GQR1XS
A204	NWjhbG9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGq1dWdKSzVyPUG2MlIxODZizszN	MorwV2FPT0WU
NCI-H1299	M2K3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zEXWlEPTB;MU[uNlI6OSEQvF2=	M3\FVnNCVkeHUh?=
VMRC-RCZ	NIL3VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILEN5hKSzVyPUG2MlI2QTJizszN	NIflXnRUSU6JRWK=
BxPC-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi5WGVlUUN3ME2xOk4zQDV4IN88US=>	NUTXbZRbW0GQR1XS
NCI-H2228	M3fId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTF4LkWxOVgh\|ryP	MlP1V2FPT0WU
NCI-H23	NUG5WHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPLTWM2OD1zNj62NFc5KM7:TR?=	M{\QVnNCVkeHUh?=
NKM-1	NUXvSlJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvmTFM4UUN3ME2xO{4xOTh7IN88US=>	MnL3V2FPT0WU
KYSE-70	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC1TWM2OD1zNz6yPFkh\|ryP	M{DZOnNCVkeHUh?=
BB49-HNC	NEflc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFriUWtKSzVyPUG3MlU3QDZizszN	MlHBV2FPT0WU
SCC-15	NU[wfpVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFmzcIRKSzVyPUG3Mlg1PzNizszN	NHvpcpRUSU6JRWK=
D-247MG	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTF5LkmyOFch\|ryP	MVnTRW5ITVJ?
BB30-HNC	NUTZUZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPOUJJ7UUN3ME2xPE4xOzF6IN88US=>	NXq2WJNMW0GQR1XS
CAL-85-1	NFXq[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHrS4ZmUUN3ME2xPE4yQDB7IN88US=>	MlrvV2FPT0WU
HT-3	M3H6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\4TI1rUUN3ME2xPE4{QTd5IN88US=>	M2LqdHNCVkeHUh?=
KYSE-410	M1;P[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq0RnVkUUN3ME2xPE41PTd5IN88US=>	M4\WTXNCVkeHUh?=
SW982	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGS5RmpKSzVyPUG4MlU3PDlizszN	MUfTRW5ITVJ?
SW962	NFPSfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojXTWM2OD1zOD61O\|AzKM7:TR?=	MnfkV2FPT0WU
Ramos-2G6-4C10	M4\4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTF6LkW5Nlch\|ryP	NV;pVXZyW0GQR1XS
OC-314	M4[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7nTWM2OD1zOD63N\|g1KM7:TR?=	M1XtWnNCVkeHUh?=
LS-123	M{X1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWntb5BZUUN3ME2xPE44QTBzIN88US=>	NWfHNZpJW0GQR1XS
D-502MG	M{HJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTF6LkixN\|kh\|ryP	MXXTRW5ITVJ?
RO82-W-1	NG\lcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:xTWM2OD1zOD64Nlg5KM7:TR?=	NGfnPWJUSU6JRWK=
HuO9	NHWxTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTtc4FDUUN3ME2xPU4yOzd7IN88US=>	NXO1N\|FSW0GQR1XS
ETK-1	NHzKXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfaTWM2OD1zOT6xPFI4KM7:TR?=	M4fzWHNCVkeHUh?=
SNU-387	NX3UXVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17oNWlEPTB;MUmuNVg5QSEQvF2=	NVLkbnZLW0GQR1XS
SW1573	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn4PJB2UUN3ME2xPU4yQTZ7IN88US=>	Mnz2V2FPT0WU
NTERA-S-cl-D1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDKTWM2OD1zOT6yNFA4KM7:TR?=	M2ixUnNCVkeHUh?=
SF126	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTF7LkO1NFIh\|ryP	NEjPOVJUSU6JRWK=
Calu-3	M1fQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHMflNPUUN3ME2xPU41OjN5IN88US=>	M{Xkd3NCVkeHUh?=
NCI-H1048	M{PIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUWwcpdLUUN3ME2yNE4{OjZ4IN88US=>	MXTTRW5ITVJ?
NCI-H226	NYjLOZppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\oZ\|JKSzVyPUKwMlQ{QTlizszN	M2ruZ3NCVkeHUh?=
FTC-133	M2\vcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTJyLkS3NFMh\|ryP	MmfjV2FPT0WU
SF539	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Tz[WlEPTB;MkCuOVE4OiEQvF2=	NUPmc5Y{W0GQR1XS
TE-6	NImwN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTJyLkiwOlch\|ryP	M4TWcnNCVkeHUh?=
UMC-11	NYrhWJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzQNWJ5UUN3ME2yNE46OTZ2IN88US=>	MV3TRW5ITVJ?
Becker	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPXdWtQUUN3ME2yNU4yOTF6IN88US=>	NGjONoRUSU6JRWK=
KP-4	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrweGdKSzVyPUKxMlEyQTZizszN	MXvTRW5ITVJ?
ChaGo-K-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXe4dHEyUUN3ME2yNU4{PjJ5IN88US=>	NY[wflV2W0GQR1XS
CFPAC-1	M4TrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTW[5pJUUN3ME2yNU4{QDV6IN88US=>	NXj2PGxUW0GQR1XS
A498	MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnXTWM2OD1{MT61N\|EzKM7:TR?=	M{OwXnNCVkeHUh?=
NCI-H1755	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nnOWlEPTB;MkGuOlc1OSEQvF2=	NYT2SnFYW0GQR1XS
TI-73	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInCc4pKSzVyPUKyMlMzQCEQvF2=	NXHkR5Z[W0GQR1XS
NCI-H441	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml:2TWM2OD1{Mj61Olg6KM7:TR?=	M1HYUnNCVkeHUh?=
CaR-1	NX3ubFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTrO49HUUN3ME2yN{4xOjF\|IN88US=>	NXLZVmcyW0GQR1XS
HCC1806	NVXLT5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\6ZmlEPTB;MkOuNFU5OyEQvF2=	MkP0V2FPT0WU
SNU-449	NGq5XodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jzTGlEPTB;MkOuN\|I6KM7:TR?=	MYLTRW5ITVJ?
EKVX	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7tZnNKSzVyPUKzMlM6ODlizszN	MlXKV2FPT0WU
DMS-114	M4\1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTlS\|NqUUN3ME2yN{42PzZ3IN88US=>	MVvTRW5ITVJ?
A704	NEKy[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vKU2lEPTB;MkOuOlExOyEQvF2=	M1jhdXNCVkeHUh?=
LC-2-ad	M3rqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJ\|Lk[xOFch\|ryP	M362WnNCVkeHUh?=
VM-CUB-1	M134bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofUTWM2OD1{Mz63N\|QyKM7:TR?=	NHThe3pUSU6JRWK=
PC-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLjUoQ3UUN3ME2yOE4xPTJ4IN88US=>	M1PxO3NCVkeHUh?=
HEL	NX7oOYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLQSItKSzVyPUK0MlA5PjVizszN	M2X2WnNCVkeHUh?=
ABC-1	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELyOo1KSzVyPUK0MlI4OjlizszN	NFzVNGxUSU6JRWK=
COLO-680N	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHLb4FKSzVyPUK0MlQ4PjRizszN	M4LrdXNCVkeHUh?=
MZ1-PC	M370dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX30Z4lQUUN3ME2yOE43QDdizszN	NFjoOGxUSU6JRWK=
NCI-H69	NFfxd\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L1XGlEPTB;MkSuO\|M2PCEQvF2=	NHXpN4dUSU6JRWK=
TE-1	M1;6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHGzPIdKSzVyPUK1MlA1QTlizszN	M{naO3NCVkeHUh?=
EW-3	M3fTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPRVGFDUUN3ME2yOU4yOTNizszN	NIX4R3pUSU6JRWK=
PANC-08-13	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M32xXWlEPTB;MkWuPFExOyEQvF2=	MkjCV2FPT0WU
NMC-G1	M{K2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH5U5NKSzVyPUK2MlAxQDhizszN	MkHYV2FPT0WU
BT-20	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJ4LkS1OFMh\|ryP	MU\TRW5ITVJ?
TGBC24TKB	NYCwUJJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{e3VGlEPTB;Mk[uO\|M{OSEQvF2=	MXzTRW5ITVJ?
TE-11	NH7qSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTJ4Lkm4PVUh\|ryP	MYXTRW5ITVJ?
ESS-1	NUPISohzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vxS2lEPTB;MkeuN\|IyPiEQvF2=	M3;mOnNCVkeHUh?=
JVM-3	NWT2b3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf1TWM2OD1{Nz62OFc2KM7:TR?=	M4PXUXNCVkeHUh?=
C3A	M4jIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LoNGlEPTB;MkeuPFQ6PiEQvF2=	M2PIVXNCVkeHUh?=
MDA-MB-157	M2XDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr6[pE6UUN3ME2yO{45PzV\|IN88US=>	NGnFPZpUSU6JRWK=
KLE	NHr5WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTObINKSzVyPUK4MlExPThizszN	NVTjO3l4W0GQR1XS
ES1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTmTWM2OD1{OD6xPFM5KM7:TR?=	M2Lj[3NCVkeHUh?=
CAL-120	NXjLc29kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJ6LkO5PVkh\|ryP	M1rLO3NCVkeHUh?=
NCI-N87	NULwS5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\LeVhDUUN3ME2yPE42OTB3IN88US=>	NWHje3J2W0GQR1XS
RPMI-8226	NXLDOo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnvSGxxUUN3ME2yPU4yQDR\|IN88US=>	MVLTRW5ITVJ?
COR-L88	M{Gw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[3O5FuUUN3ME2yPU4zPDF7IN88US=>	NVTpUmtmW0GQR1XS
UACC-893	NV7qZolQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTJ7LkOxN\|ch\|ryP	M1fTfHNCVkeHUh?=
C8166	M3XzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S1W2lEPTB;MkmuPVk6PiEQvF2=	MorIV2FPT0WU
J82	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f5bWlEPTB;M{CuPFE1PyEQvF2=	MW\TRW5ITVJ?
PFSK-1	NXnseHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYG2OXBzUUN3ME2zNU4xPjV7IN88US=>	NF\qXXFUSU6JRWK=
COLO-684	NXTObI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rHcmlEPTB;M{GuOFM4PCEQvF2=	MUTTRW5ITVJ?
CAL-72	NXvUTGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK3ToZ{UUN3ME2zNU42PzJ7IN88US=>	MlTtV2FPT0WU
SNB75	NF3ycXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TzUmlEPTB;M{GuPFk4KM7:TR?=	M1LrUnNCVkeHUh?=
MDA-MB-415	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnjWZdKSzVyPUOxMlk4PjJizszN	MX7TRW5ITVJ?
SiHa	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPkTWM2OD1\|Mj60O\|EyKM7:TR?=	MVrTRW5ITVJ?
NCI-H1648	NVjFXFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTN{LkmzOFUh\|ryP	M4fNVnNCVkeHUh?=
EFO-21	NUm3WVRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTN\|LkCwOUDPxE1?	MkmxV2FPT0WU
HCC38	M{P4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7uPYZMUUN3ME2zN{4{QDRzIN88US=>	M1OxTXNCVkeHUh?=
IA-LM	NUfncld6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTN\|Lke4PFkh\|ryP	MVnTRW5ITVJ?
CTV-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPmNZR7UUN3ME2zN{46Pzh4IN88US=>	M2fmdnNCVkeHUh?=
NCI-H446	NX3vRmtbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3Qb\|ZXUUN3ME2zOE4zPjh7IN88US=>	MkjZV2FPT0WU
IST-SL1	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVT1e3JkUUN3ME2zOE44PDB6IN88US=>	MUXTRW5ITVJ?
EW-22	NYXVNnFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\rdmlEPTB;M{SuO\|c2QSEQvF2=	MoHxV2FPT0WU
JEG-3	NVHDeXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonRTWM2OD1\|Nj6xO\|Y3KM7:TR?=	NXXhflBIW0GQR1XS
LU-65	NXvibGhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoG5TWM2OD1\|Nj6yPVg2KM7:TR?=	NXjiXng{W0GQR1XS
NCI-H596	M1yyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n4cGlEPTB;M{[uPVU6OSEQvF2=	MUPTRW5ITVJ?
KNS-81-FD	NXjkd\|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3ld4tKSzVyPUO3MlE1PSEQvF2=	Ml35V2FPT0WU
NCI-H1793	MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTN5LkewPFYh\|ryP	Moj0V2FPT0WU
NCI-H460	NGH6bm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljOTWM2OD1\|OD6wPFc{KM7:TR?=	NVjZUWZlW0GQR1XS
MPP-89	M2HIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vTUGlEPTB;M{muOVg5PiEQvF2=	NHfVSZVUSU6JRWK=
D-542MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjOTWM2OD1\|OT64OFM3KM7:TR?=	M4D0VXNCVkeHUh?=
JAR	NEDofnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPtTWM2OD12MD60O\|A2KM7:TR?=	MWLTRW5ITVJ?
NCI-H209	M4DYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH25RXFKSzVyPUSwMlY4PyEQvF2=	NHrZSWlUSU6JRWK=
G-402	NF7x[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu2TWM2OD12MT6zPVk{KM7:TR?=	MWDTRW5ITVJ?
IST-MES1	NITURVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnuTWM2OD12Mj6xPVM2KM7:TR?=	M4LwWXNCVkeHUh?=
Daoy	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUj5c5FRUUN3ME20Nk42PDdzIN88US=>	NFOwd5NUSU6JRWK=
EW-11	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHDRZg2UUN3ME20N{4yOjFzIN88US=>	Mo\sV2FPT0WU
Saos-2	NYjEVYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTR\|LkG1N\|ch\|ryP	M1vlU3NCVkeHUh?=
no-10	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnjTWM2OD12Mz6xO\|AzKM7:TR?=	MWHTRW5ITVJ?
HCC1395	NEHsU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1izfmlEPTB;NEOuOFY1PCEQvF2=	MlnsV2FPT0WU
HCE-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fhW2lEPTB;NEOuO\|Y3PCEQvF2=	NHv6OWFUSU6JRWK=
EW-1	NGHGPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\OTmlEPTB;NEOuPFA1QSEQvF2=	NHX0NlJUSU6JRWK=
OCUB-M	NVnDZ\|c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\STWM2OD12ND6zOlM5KM7:TR?=	MojyV2FPT0WU
IGR-1	NEXz[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTR2LkSxNVUh\|ryP	NGn6blhUSU6JRWK=
NCI-H1838	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjDWZFKSzVyPUS0MlQ{PDlizszN	Mlm1V2FPT0WU
NCI-H2405	M{nUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfPTWM2OD12ND61N\|Qh\|ryP	MnTnV2FPT0WU
GB-1	NFnNTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P6T2lEPTB;NESuO\|Q3OyEQvF2=	MYLTRW5ITVJ?
MG-63	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTR4LkC2PVYh\|ryP	NH[wXZBUSU6JRWK=
KP-N-YN	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTR4LkS2O\|kh\|ryP	M1vQcXNCVkeHUh?=
no-11	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\zSmlEPTB;NEeuNFI1PCEQvF2=	Mnq3V2FPT0WU
SW948	NUDZWYxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPnXZk6UUN3ME20O{4{Ozd5IN88US=>	MYHTRW5ITVJ?
CAMA-1	NWL2W2E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInienJKSzVyPUS3MlM1OzhizszN	NWXtUWdCW0GQR1XS
HCC1187	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH23fGRKSzVyPUS3MlUyKM7:TR?=	MWjTRW5ITVJ?
D-392MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LP[GlEPTB;NEeuOlUyPiEQvF2=	NVvrZodoW0GQR1XS
647-V	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zKb2lEPTB;NEmuN\|QyPCEQvF2=	MYjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK1/2 / ERK1/2 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK1/2 in sympathetic neurons. Immunoblots were performed with whole cell extracts from sympathetic neurons maintained in the presence of NGF and left untreated or treated with PD184352 at 0.1, 1, 2 or 10 μM for 16 hours. Antibodies to detect total ERK1/2 and phospho-ERK1/2 were used. p-ERK5 / ERK5 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK5 in sympathetic neurons.	21762482
Growth inhibition assay	Cell viability; PubMed: 29989268 Cancer Sci Relative viability of DU145CR cells treated with PD184352 was significantly less than that of DU145 cells in WST assay.	29989268

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	- Collapse MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	- Collapse Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: PTC cells in athymic mice Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Features:More potent than PD0325901 or AZD6244.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)